

Supplementary Table S2. A Comparison of EC₅₀ and Efficacy of CXCR3 agonists and CCL5 on migratory responses of PBMC from non-smokers, smokers and patients with COPD.

		EC ₅₀ nM	Maximal concentration nM
CXCL9	Non-smoker	2.7 ± 0.6	33.1 ± 11.3
	Smoker	4.1 ± 0.8	31.9 ± 3.7
	COPD	3.3 ± 0.4	51.9 ± 12.9
CXCL10	Non-smoker	2.8 ± 0.6	24.6 ± 5.2
	Smoker	2.3 ± 0.4	29.9 ± 2.0
	COPD	2.3 ± 0.5	25.0 ± 2.9
CXCL11	Non-smoker	2.7 ± 0.6	27.5 ± 3.6
	Smoker	3.5 ± 0.9	28.7 ± 2.6
	COPD	2.4 ± 0.6	31.0 ± 2.1
CCL5	Non-smoker	2.7 ± 0.6	46.6 ± 15.4
	Smoker	7.5 ± 2.4	25.4 ± 3.5
	COPD	5.6 ± 2.8	32.3 ± 6.5

Data are presented as mean ± SEM where n = 6-10.